Finally, in the same trial, when pembrolizumab was used alone as first-line treatment in patients with PDL1-positive tumors, ORR was 26%, showing promising anti-tumor activity despite a higher rate of significant adverse side effects [57]. The gene discussed is CD274; the disease is neoplasm.